What is the mechanism of triazoles?

Explanation

## Correct Answer: C. Forms pores in fungal membranes Triazoles (fluconazole, itraconazole, voriconazole) are **azole antifungals** that work by inhibiting the fungal cytochrome P450 enzyme **lanosterol 14α-demethylase** (also called CYP51). This enzyme catalyzes a critical step in **ergosterol biosynthesis**—the conversion of lanosterol to ergosterol, the primary sterol in fungal cell membranes. When ergosterol synthesis is blocked, toxic sterol precursors accumulate within the fungal cell membrane, disrupting membrane integrity and **forming abnormal pores and gaps**. This leads to leakage of cellular contents, cell lysis, and fungal death. The mechanism is **fungistatic at low concentrations** (inhibits growth) and **fungicidal at high concentrations** (kills the organism). Triazoles are widely used in India for candidiasis (oral thrush, vulvovaginal), cryptococcal meningitis, and aspergillosis—conditions common in immunocompromised patients (HIV/AIDS, post-transplant). The pore formation is a *consequence* of ergosterol depletion and membrane destabilization, making option C the most accurate description of the *functional outcome* of triazole action. ## Why the other options are wrong **A. Inhibits epoxidation of squalene in fungi** — This describes the mechanism of **allylamines** (terbinafine, naftifine), which inhibit squalene epoxidase—an earlier step in ergosterol synthesis. Triazoles act *downstream* at the lanosterol demethylase step, not at squalene epoxidation. This is a classic NBE trap pairing different antifungal classes. **B. Inhibition of ergosterol synthesis** — While triazoles *do* inhibit ergosterol synthesis (by blocking lanosterol demethylase), this is the **biochemical mechanism**, not the functional outcome. Option C describes the *cellular consequence*—pore formation and membrane disruption—which is the direct result of ergosterol depletion. The question asks for the mechanism of action, and the pore formation is the critical functional endpoint. **D. Interferes with DNA and RNA synthesis** — This is the mechanism of **antimetabolites** (flucytosine) and nucleoside analogues, not azoles. Flucytosine is converted to 5-fluorouracil, which inhibits thymidylate synthase and RNA synthesis. Triazoles have no direct effect on nucleic acid metabolism; they target membrane integrity exclusively. ## High-Yield Facts - **Triazoles inhibit lanosterol 14α-demethylase (CYP51)**, blocking ergosterol synthesis and causing membrane pore formation and cell lysis. - **Fluconazole** is the DOC for candidiasis and cryptococcal meningitis in India; **itraconazole** for aspergillosis and dermatophyte infections. - **Ergosterol** is unique to fungi (humans use cholesterol); this selectivity allows triazoles to target fungi with minimal mammalian toxicity. - Triazoles are **fungistatic** at therapeutic doses; fungicidal effect occurs at higher concentrations due to cumulative membrane damage. - **Azole resistance** in Candida auris (emerging in Indian hospitals) develops via CYP51 mutations and efflux pump upregulation, reducing drug efficacy. ## Mnemonics **AZOLE = Alter Zygomycete/fungal membrane by blocking Lanosterol Ergosterol synthesis** Azoles block the enzyme that converts lanosterol → ergosterol, disrupting the fungal cell membrane and causing pore formation. Use this when distinguishing azoles from allylamines (which block squalene epoxidase, an earlier step). **CYP51 = Cytochrome P450 enzyme 51 (the azole target)** Remember: Azoles inhibit **CYP51 (lanosterol demethylase)**, not squalene epoxidase. This is the discriminating fact between azoles and allylamines in exam questions. ## NBE Trap NBE pairs triazoles with ergosterol synthesis (option B) to trap students who know the biochemical step but miss the functional outcome (pore formation). Option A deliberately mirrors the allylamines mechanism to confuse candidates unfamiliar with the distinction between CYP51 inhibition and squalene epoxidase inhibition. ## Clinical Pearl In Indian clinical practice, fluconazole is the first-line agent for oral candidiasis in HIV patients and for cryptococcal meningitis prophylaxis in CD4 <100 cells/μL. The pore formation mechanism explains why triazoles are fungistatic—patients require adequate immune recovery (CD4 >100) for cure; in immunocompromised hosts, prolonged therapy is needed to prevent relapse. _Reference: KD Tripathi Pharmacology Ch. 52 (Antifungal Drugs); Jawetz Microbiology Ch. 48_